Hims & Hers Q2 revenue beats estimates but loss widens due to restructuring charges

Hims & Hers Health reported a 38% year-over-year revenue increase to $753.2 million in Q2 2026, surpassing analyst expectations of $699 million. However, the company posted a larger-than-expected loss of $0.37 per share, driven by restructuring costs linked to its shift toward branded GLP-1 weight-loss products. Subscriber numbers grew 19% to nearly 2.9 million. The company raised its full-year revenue forecast to $3.1-$3.3 billion and expects Q3 revenue between $880 million and $900 million. CEO Andrew Dudum emphasized the focus on expanding its health platform and developing a doctor-led AI clinical engine. Shares fell about 1% following the results.